eTheRNA immunotherapies, a clinical-stage company developing immunotherapies for the treatment of cancer and infectious diseases, has announced the opening of a subsidiary, eTheRNA Asia, with offices located in the Sheung Wan area of Hong Kong.
The Asia-Pacific region is growing in importance in the healthcare sector and this subsidiary will serve as a focus for the company’s increasing commercial activities in this area. In particular, the subsidiary will support business and investor relations in China and especially the relationship between eTheRNA and its strategic partner, China Grand Pharmaceutical and Healthcare Holdings. CGP and eTheRNA’s relationship is centred on a joint venture company, Nanjing AuroRNA Biotechnology Company.
Steven Powell, CEO of eTheRNA, said: “The strategic aim under the Healthy China 2030 plan is to improve cancer care and develop truly innovative oncology drugs in China itself. Through our Chinese investors and partners we have developed strong links with the region and look forward to increasing our activities and contributing to help fulfil this ambition.”
